Mild Cognitive ImpairmentNCT00243451
Early Detection of Mild Cognitive Impairment in Individual Patients
An observational study of Mild Cognitive Impairment and Mild Alzheimer's Disease, run by Louisiana State University Health Sciences Center Shreveport at 1 site in United States.
Trial summary
Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of [18]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating. Read more about this study
- Who is it for?
- Ages 55 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Mild Cognitive Impairment, Mild Alzheimer's Disease
- What is being tested?
- PET scan & fMRI
- How many people
- 34 participants
- Where
- 1 siteUnited States
- Study dates
- Sep 2003to Jul 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects must have a diagnosis of MCI or mild AD.
MCI Inclusion Criteria (patients):
MCI criteria met:
- Memory complaint, preferably corroborated by an informant.
- Objective memory impairment (based on cognitive test scores).
- Normal general cognitive function.
- Intact ADL.
- Not demented.
- At least 10 years of education, or GED, or equivalent.
- Patients with ApoE4 positive homozygous or heterozygous status and/or first-degree relative with probable AD are preferred, but patients who meet all other criteria including well-defined MCI criteria will be accepted.
- Age: 55-85
- Have normal or clinically unimportant physical exam, beyond those consistent with a diagnosis of MCI.
- Able to give informed consent, or assent and informed consent from a legal representative.
- Centrally acting medications will be closely tracked, patients on any such medications will be PET-scanned only after a 24-hour washout, with meds restarted immediately after the scan.
- Because depression and depressive pseudodementia are often prodromal to cognitive decline, these diagnoses will not be exclusive.
- MRI findings must be normal or unremarkable for the age of the patient. Examples of abnormal (exclusory) findings are occult lacunar infarct, arteriovenous malformation) Examples of non-exclusory findings include mild atrophy, mild to moderate periventricular white matter changes. Other MRI findings will be evaluated in consultation with coinvestigator neuroradiologists and clinical judgment will be used to determine if the subject can continue in the study.
MCI Exclusion Criteria (patients):
- Other neuropsychiatric diagnoses (e.g., stroke, head trauma, any psychotic disorder, Parkinson's) other than MCI.
- Major medical illness (e.g., diabetes, severe or uncontrolled hypertension), especially potential secondary causes of cognitive decline (e.g., hypothyroidism).
- Disease, combination of disease, or presentation that, in the clinician's judgment, could introduce intolerable variance into the PET brain scan image (example: coronary artery disease, hypercholesterolemia, on 5 medications, HTN 2 yrs controlled with meds, random glucose of 125, but no Dx of DM, Hx of ?TIA).
- Current substance or alcohol dependence or history of same, and no alcohol or substance abuse within the last eight weeks.
Mild Alzheimer's Disease (AD) Inclusion criteria (patients):
- You must have a Mini Mental State Examination score of greater than 20.
- You must have one or more of these signs and symptoms of mild AD:
Cognitive impairment manifested as memory problems, problems with language, difficulty carrying out motor activities, difficulty naming things, and/or problems planning or organizing, all of which impair function and are worsening over time.
- You must have at least 10 years of education, or a GED, or its equivalent.
- We will be drawing blood to determine your ApoE genotype. ApoE4 is a risk factor for Alzheimer's disease. We will share these results with you, if you desire to know the results. ApoE4 is only a risk factor. That means it is possible to get Alzheimer's without being ApoE4 positive, and it is possible to be ApoE4 positive and not get Alzheimer's. If you are positive for the ApoE4 genetic marker, you can be included. If you do NOT have the ApoE4 genetic marker, then you must have all other criteria.
- Age: 55-85.
- Normal or clinically unimportant physical exam, beyond those consistent with a diagnosis of mild AD.
- Able to give informed consent, or assent and informed consent from a legal representative. You will be assessed for capacity and assent/consent obtained as appropriate based on the Consensus Recommendations for Research Consent for Cognitively Impaired Adults (2004, Alzheimer's Disease Association Disorder, 18 (3):171-175).
- If you take medications that have an effect on the brain, they will be closely monitored. You will be PET-scanned only after a 24-hour washout of this medication(s), but this medication(s) will be restarted immediately after the scan.
Mild Alzheimer's Disease (AD) Exclusion Criteria:
- Any problems related to the brain or mental disorders (e.g., stroke, head trauma, any psychotic disorder, Parkinson's) other than mild AD. Some mood disorders will be acceptable because depression is often a precursor to mild AD.
- You will get an MRI of your brain taken on the second visit, and a radiologist will read it. If there are any abnormal findings, you will be told, and these findings will be forwarded to your medical doctor. These findings may or may not result in your exclusion from the study.
- Any major medical illness (e.g., diabetes, severe or uncontrolled hypertension), especially potential secondary causes of cognitive decline (e.g., hypothyroidism).
- Any disease, combination of disease, or presentation that, in the clinician's judgment, could introduce intolerable variance into the PET brain scan image.
- Current diagnosis of substance or alcohol dependence or a history of same, and no alcohol or substance abuse within the last eight weeks.
MCI Inclusion criteria (controls)
- Normal cognitive screening exam.
- Age: 55-85.
- At least 10 years of education or GED, or equivalent.
- Socioeconomic status, age, and sex matched. Able to give informed consent, or assent and informed consent from a legal representative.
- Centrally acting medications will be closely tracked, patients on any such medications will be PET-scanned only after a 24-hour washout, with meds restarted immediately after the scan.
MCI Exclusion criteria (controls)
- First-degree relative with dementia or clinically relevant memory problems.
- Neuropsychiatric diagnoses (e.g., stroke, head trauma, depression, any psychoses).
- Major medical illness (e.g., diabetes, severe /uncontrolled hypertension, hypothyroidism).
- Current substance or alcohol dependence or history of same, and no alcohol or substance abuse within the last eight weeks.
- MRI findings must be normal or unremarkable for the age of the patient. Examples of abnormal (exclusory) findings are occult lacunar infarct, arteriovenous malformation) Examples of non-exclusory findings include mild atrophy, mild to moderate periventricular white matter changes. Other MRI findings will be evaluated in consultation with coinvestigator neuroradiologists and clinical judgment will be used to determine if the subject can continue in the study.
- Disease, combination of disease, or presentation that, in the clinician's judgment, could introduce intolerable variance into the PET brain scan image (example: coronary artery disease, hypercholesterolemia, on 5 medications, HTN 2 yrs controlled with meds, random glucose of 125, but no Dx of DM, Hx of ?TIA).
Dropout criteria (all):
Subjects that begin the study and are not able to finish the study will be tracked. Ongoing criteria for termination from the study will include:
- Adverse events intolerable to the patient that prevent continued involvement in the study.
- New onset medical disorder of such significance as to prohibit further involvement.
- Initiation or recurrence of alcohol or substance abuse/dependence.
- Subject withdraws consent for any reason.
Trial locations and contacts
1 site in 1 country.
United States1 site
Louisiana State University Health Sciences Center
Shreveport, Louisiana, 71103
About this study
Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of [18]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.
Read the detailed description
Our goal with this proposal is a prospective, longitudinal study that will examine subjects over a three-year span to establish the presence of MCI, evaluate progression of disease, and determine the validity of this method in detecting early MCI. Specifically, we predict that by using our Cognitive Decline Index (CDI) method of objective examination of FDG PET brain images from patients diagnosed with MCI or mild AD, we can accurately discriminate very early abnormalities in cerebral metabolism, and that this research method can be validated and translated into a clinically useful tool for the early detection of MCI. Our long-range goals are the development of methods and tools that enable the detection of pathology in individual patients at risk for cognitive impairment.
- Being tested
- PET scan & fMRI
- Medical subject headings
- Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PET scan & fMRIOther
Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine if the Cognitive Decline Index will discriminate subtle lesions earlier than the standard analysis of the Nuclear Medicine physician.
Measured: within the next 3 years
Secondary outcomes (1)
Determine if sensitivity, specificity, receiver-operator characteristics, and predictive value of our method are appropriate for translation into a clinically useful tool.
Measured: within the next three years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Oct 2005 (estimated)
- Study startSep 2003
- Primary completionJul 2011
- Study completionJul 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mild Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 34 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Louisiana State University Health Sciences Center Shreveport
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, James C. Patterson, II, MD. Ph, Louisiana State University Health Sciences Center Shreveport
- Investigators
- James Patterson, MD PhD, Principal investigator, Louisiana State University Health Sciences Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00243451
- Sponsor's protocol ID
- LSUHSC H04-049
- Status last verified
- Sep 2011
- First submitted
- 13 Sep 2005
- Last updated
- 7 Sep 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Sep 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Detection of Mild Cognitive Impairment in Individual Patients
- ClinicalTrials.gov ID
- NCT00243451
- Acronym / sponsor ID
- LSUHSC H04-049
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 34 participants (estimated)
- Lead sponsor
- Louisiana State University Health Sciences Center ShreveportUniversity, hospital or other
- Study start
- Sep 2003
- Primary completion
- Jul 2011 (actual)
- Study completion
- Jul 2011 (actual)
- First posted
- 24 Oct 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of [18]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.
Detailed description
Our goal with this proposal is a prospective, longitudinal study that will examine subjects over a three-year span to establish the presence of MCI, evaluate progression of disease, and determine the validity of this method in detecting early MCI. Specifically, we predict that by using our Cognitive Decline Index (CDI) method of objective examination of FDG PET brain images from patients diagnosed with MCI or mild AD, we can accurately discriminate very early abnormalities in cerebral metabolism, and that this research method can be validated and translated into a clinically useful tool for the early detection of MCI. Our long-range goals are the development of methods and tools that enable the detection of pathology in individual patients at risk for cognitive impairment.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 55 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects must have a diagnosis of MCI or mild AD.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PET scan & fMRISubjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit. | Other | – |
Primary outcome
Determine if the Cognitive Decline Index will discriminate subtle lesions earlier than the standard analysis of the Nuclear Medicine physician.
Time frame: within the next 3 years
1 secondary outcome
Determine if sensitivity, specificity, receiver-operator characteristics, and predictive value of our method are appropriate for translation into a clinically useful tool.
Time frame: within the next three years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Sep 2011.
Related trials for Mild Cognitive Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
RecruitingObservational study
InRAD Observational Study
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James Patterson, MD PhD principal investigator
Louisiana State University Health Sciences Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mild Cognitive Impairment and Mild Alzheimer's Disease, run by Louisiana State University Health Sciences Center Shreveport at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Sep 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine if the Cognitive Decline Index will discriminate subtle lesions earlier than the standard analysis of the Nuclear Medicine physician. (time frame: within the next 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2011.